Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

Currently, there is only one U.S. government-approved treatment available for fatty liver disease, Rezdiffra (resmetirom), researchers said. It works by activating a thyroid hormone receptor that ...

While Berberine is touted as a natural alternative to Ozempic, its AMPK modulation differs from GLP-1 pathways, highlighting ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and ...